TPF
REGN icon

Tribridge Partners Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Tribridge Partners Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Sell
330
-13
-4% -$8.85K 0.09% 74
2026
Q1 		$261K Hold
343
– – 0.11% 66
2025
Q4 		$265K Hold
343
– – 0.11% 61
2025
Q3 		$206K Buy
+343
New +$194K 0.09% 70

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tribridge Partners Financial's REGN Position: Q2 2026 in Review

Tribridge Partners Financial reduced its Regeneron Pharmaceuticals (REGN) stake by 3.8% in Q2 2026, selling an estimated $8.85K and leaving 330 shares worth $220K. The position accounts for 0.09% of the portfolio, ranked #74.

Tribridge Partners Financial first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $265K in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Tribridge Partners Financial held 330 shares of Regeneron Pharmaceuticals worth $220K as of Q2 2026.
  • Tribridge Partners Financial sold 13 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
  • Regeneron Pharmaceuticals made up 0.09% of Tribridge Partners Financial's portfolio in Q2 2026, its #74 holding.
  • Tribridge Partners Financial first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Tribridge Partners Financial's Regeneron Pharmaceuticals position peaked at $265K in Q4 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Tribridge Partners Financial's 13F filing for Q2 2026, filed 4 Aug 2026.